Literature DB >> 16437718

Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease.

Doris Meister1, Subrata Ghosh.   

Abstract

AIM: To investigate the influence of fish oil enriched enteral diet on intestinal tissues taken from Crohn's disease (CD), ulcerative colitis (UC) and non-inflamed non-IBD control patients in vitro.
METHODS: Colonoscopic biopsies from patients with active CD (n = 4), active UC (n = 7), and non-inflamed non-IBD control patients (n = 4) were incubated (three dilutions of 1:20, 1:10, and 1:5) with Waymouth's culture medium and enteral elemental diet (EO28, SHS, Liverpool, UK) modified in the fatty acid composition with fish oil (EF) in an organ culture system for 24 h. In each experimental set-up, incubation with Waymouth's medium alone as control was included. Tissue viability was assessed by adding bromodeoxyuridine (BrdU) to the culture fluid and immunohistochemically staining for BrdU uptake. Cytokine ratio of IL-1ra/IL-1beta (low ratio indicative of inflammation) and production of those cytokines as a percentage of medium control were assayed in the culture supernatant.
RESULTS: Incubation of CD-affected tissue with EF (1:20, 1:10, and 1:5) modestly and non-significantly increased IL-1ra/IL-1beta ratio as compared with medium control (CD 39.1+/-16.1; 26.5+/-7.8, 47.1+/-16.8 vs control 13.0+/-2.2), but incubation of UC-affected tissues increased IL-1ra/IL-1beta ratio significantly in all three dilutions (UC 69.1+/-32.2, P<0.05; 76.1+/-36.4, P = 0.05; 84.5+/-37.3, P<0.02; vs control 10.2+/-3.7). Incubation of non-inflamed non-IBD control tissue did not increase the IL-1ra/IL-1beta ratio in any dilution compared to medium control (69.3+/-47.0, 54.1+/-30.6, 79.4+/-34.0 vs control 76.1+/-37.3). Average percentage production of IL-1beta indexed against medium control was significantly less in UC after EF incubation as compared with CD (UC 24.0+/-4.8 vs CD 51.8+/-8.1; P<0.05). Average percentage production of IL-1ra was markedly higher in UC (135.9+/-3.4) than that in control patients (36.5+/-4.3) (P<0.0001).
CONCLUSION: IBD tissues, after incubation with elemental diet modified in its fatty acid composition with fish oil, show an increase in IL-1ra/IL-1beta cytokine ratio. This effect of omega-3 fatty acid modulation is significantly more marked in UC compared with CD and is accompanied by both a reduction of IL-1beta and increase of IL-1ra. The positive direct anti-inflammatory effect of elemental diet with fish oil in tissue affected with UC suggests dietary treatment of UC may be possible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437718      PMCID: PMC4725180          DOI: 10.3748/wjg.v11.i47.7466

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Effects of fish oil and n-3 fatty acids on the regulation of delta9-fatty acid desaturase mRNA and -activity in rat liver.

Authors:  T Løchsen; H Ormstad; H Braud; B Brodal; E N Christiansen; H Osmundsen
Journal:  Lipids       Date:  1999       Impact factor: 1.880

Review 2.  Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids.

Authors:  R F Grimble; P S Tappia
Journal:  Z Ernahrungswiss       Date:  1998

Review 3.  Dietary fatty acids and the immune system.

Authors:  P C Calder
Journal:  Nutr Rev       Date:  1998-01       Impact factor: 7.110

4.  n-3 fatty acids only delay early relapse of ulcerative colitis in remission.

Authors:  K Loeschke; B Ueberschaer; A Pietsch; E Gruber; K Ewe; B Wiebecke; W Heldwein; R Lorenz
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

5.  Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition.

Authors:  Y Z Almallah; A El-Tahir; S D Heys; S Richardson; O Eremin
Journal:  Eur J Clin Invest       Date:  2000-01       Impact factor: 4.686

Review 6.  n-3 fatty acid supplements in rheumatoid arthritis.

Authors:  J M Kremer
Journal:  Am J Clin Nutr       Date:  2000-01       Impact factor: 7.045

Review 7.  Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites.

Authors:  V A Ziboh; C C Miller; Y Cho
Journal:  Am J Clin Nutr       Date:  2000-01       Impact factor: 7.045

8.  Immunohistochemical detection of abnormal cell proliferation in colonic mucosa of subjects with polyps.

Authors:  R G Wilson; A N Smith; C C Bird
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

9.  Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

Authors:  S Dionne; I D D'Agata; J Hiscott; T Vanounou; E G Seidman
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

10.  Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.

Authors:  V Casini-Raggi; L Kam; Y J Chong; C Fiocchi; T T Pizarro; F Cominelli
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

View more
  12 in total

Review 1.  Role of diet in the management of inflammatory bowel disease.

Authors:  Nirooshun Rajendran; Devinder Kumar
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

Review 2.  Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer.

Authors:  Kazuki Moro; Masayuki Nagahashi; Rajesh Ramanathan; Kazuaki Takabe; Toshifumi Wakai
Journal:  World J Clin Cases       Date:  2016-07-16       Impact factor: 1.337

3.  Detection of inflammatory bowel disease by proton magnetic resonance spectroscopy (1H MRS) using an animal model.

Authors:  Sonal Varma; Ranjana Bird; Michael Eskin; Brion Dolenko; Jayadev Raju; Tedros Bezabeh
Journal:  J Inflamm (Lond)       Date:  2007-11-26       Impact factor: 4.981

4.  Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients.

Authors:  Cheng-Jen Ma; Jin-Ming Wu; Hsiang-Lin Tsai; Ching-Wen Huang; Chien-Yu Lu; Li-Chu Sun; Ying-Ling Shih; Chao-Wen Chen; Jui-Fen Chuang; Ming-Hsun Wu; Ming-Yang Wang; Ming-Tsan Lin; Jaw-Yuan Wang
Journal:  Nutr J       Date:  2015-01-21       Impact factor: 3.271

5.  Elemental diets role in treatment of high ileostomy output and other gastrointestinal disorders.

Authors:  Kamran Rostami; David Al Dulaimi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

6.  Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomalto-oligosaccharides in HLA-B27 transgenic rats.

Authors:  Petya Koleva; Ali Ketabi; Rosica Valcheva; Michael G Gänzle; Levinus A Dieleman
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

Review 7.  Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer.

Authors:  Arkadiusz Michalak; Paula Mosińska; Jakub Fichna
Journal:  Front Pharmacol       Date:  2016-12-01       Impact factor: 5.810

Review 8.  Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases.

Authors:  Federica Ungaro; Federica Rubbino; Silvio Danese; Silvia D'Alessio
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

Review 9.  Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease.

Authors:  Raffi Lev-Tzion; Anne Marie Griffiths; Oren Leder; Dan Turner
Journal:  Cochrane Database Syst Rev       Date:  2014-02-28

Review 10.  Nutrition in Pediatric Inflammatory Bowel Disease: From Etiology to Treatment. A Systematic Review.

Authors:  Francesca Penagini; Dario Dilillo; Barbara Borsani; Lucia Cococcioni; Erica Galli; Giorgio Bedogni; Giovanna Zuin; Gian Vincenzo Zuccotti
Journal:  Nutrients       Date:  2016-06-01       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.